© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.
Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.
A next-generation implant maintained adequate drug levels for at least a year in an early study.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
The HIV regimen failed only a few study participants.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
The company also has plans to study monthly islatravir’s efficacy as HIV prevention among men who have sex with men.
A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
A mid-stage trial shows islatravir plus Pifeltro shows promise as two-drug HIV regimen.
A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.
Merck’s investigational antiretroviral is a reverse transcriptase translocation inhibitor.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
